Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview a four year follow-up study on the use of ibrutinib in previously treated patients with Chronic Lymphocytic Leukemia (CLL). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study
Advertisement